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ABSTRACT
Diagnosis of brucellosis can be difﬁcult in certain scenarios where conventional microbiological
techniques have important limitations. The aim of this study was to develop a LightCycler Quantitative
PCR assay in serum samples to discriminate between active and past brucellosis. In total, 110 serum
samples from 46 brucellosis patients and 64 controls, including persons who had recently been treated
for brucellosis, asymptomatic persons exposed to brucellosis, and patients with febrile syndromes
involving a differential diagnosis with brucellosis, were studied. Brucella spp.-speciﬁc sequences of the
PCR primers and probe were selected from the gene encoding an immunogenic membrane protein of
31 kDa (BCSP31). The analytical sensitivity was 1 · 101 fg of Brucella DNA. The mean threshold cycles
for brucellosis patients and controls were 31.8 ± 1.7 and 35.4 ± 1.1, respectively (p <0.001). The best cut-
off for bacterial DNA load was 5 · 103 copies ⁄mL. At this cut-off, the area under the receiver operating
characteristic curves was 0.963 (95% CI 0.920–1.005), with a sensitivity of 93.5% and a speciﬁcity of
98.4%. Under the assay conditions, the LightCycler Quantitative PCR in serum samples seems to be
highly reproducible, rapid, sensitive and speciﬁc. It is therefore a useful method for both the initial
diagnosis and the differentiation between past and active brucellosis.
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INTRODUCTION
Brucellosis remains the most common zoonotic
infection worldwide, representing a major form of
disease in humans [1]. Brucella is an intracellular
pathogen and is able to elude fusion by phago-
lysosomes, thereby enabling it to survive and even
multiply within cells of the mononuclear phago-
cyte system [2]. This intracellular survival deter-
mines the characteristic clinical proﬁle of the
disease, i.e. a ﬂuctuating course and a tendency
for there to be focal complications and relapses [3].
Clinically, brucellosis is highly polymorphic,
affecting any organ or system [4]. Despite correct
treatment, a high percentage of patients continue
to have non-speciﬁc symptoms that are difﬁcult to
interpret, with no clinical or microbiological
evidence of relapse [5].
To date, none of the conventional microbiolog-
ical methods has proved to be efﬁcient for the
post-treatment follow-up of brucellosis. Blood
cultures lack sensitivity in the diagnosis of
relapses, and serological tests are of little use, as
antibodies, both IgG and IgM, may be present for
many months after effective therapy. Addition-
ally, interpretation of serological tests is difﬁcult
in patients from endemic areas and those who are
professionally exposed to the disease [6,7].
To overcome certain limitations of conventional
microbiological techniques, PCR-basedassayshave
been proposed as a useful tool for the diagnosis of
human brucellosis [8,9]. Different studies have
shown that PCR methods are more sensitive than
cultures and more speciﬁc than serological tests,
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both for the diagnosis of acute forms and for focal
complications of the disease [10,11].
Current real-time PCR techniques involve a
faster ampliﬁcation process and enable quantiﬁca-
tion of the bacterial DNA load, which could be
useful for post-therapeutic follow-up of the infec-
tion. However, recent studies have reported the
prolonged persistence of DNAaemia in treated
patients with a favourable course and no evidence
of relapse [12,13]. A LightCycler Quantitative PCR
assay (LC Q-PCR) for serum samples was there-
fore developed, and its capacity to discriminate
between active and past brucellosis was evaluated.
PATIENTS AND METHODS
Study population
From April 2002 to March 2007, serum samples were collected
from 46 patients who received a diagnosis of brucellosis in the
Infectious Diseases Service of Carlos Haya University Hospi-
tal, Malaga, Spain.
Control serum samples were obtained from 64 subjects.
These included 36 asymptomatic patients with a history of
brucellosis, treated according to usual antibiotic regimens (13
patients immediately after treatment, ﬁve after 2–4 months,
ﬁve after 4–6 months, and 13 after 6–24 months), 12 asymp-
tomatic but exposed persons from families affected by brucel-
losis following consumption of unpasteurized cheese or milk,
and ﬁve asymptomatic persons permanently exposed to
Brucella infection in their professions (three veterinary sur-
geons and two abattoir workers) with persistently high titres of
anti-Brucella antibodies. The 64 subjects also included 11
patients with febrile syndromes of other deﬁned aetiologies,
initially involving a differential diagnosis with brucellosis:
four with acute cytomegalovirus infection, two with tubercu-
lous vertebral osteomyelitis, and one each with acute human
immunodeﬁciency virus infection, Epstein–Barr virus infec-
tion, microscopic polyangitis, giant cell arteritis, and HLA
B-27-positive ankylosing spondylitis. Approval from the Insti-
tutional Review Board and Medical Ethics Committee was
obtained before the start of the study.
In order to guarantee that all the patients with brucellosis
had active disease, cases were considered only if they fulﬁlled
one of the following criteria: ﬁrst, isolation of Brucella spp.
from blood or any other body ﬂuid or tissue sample; and
second, the presence of a typical focal complication of
brucellosis (e.g. sacroiliitis, vertebral osteomyelitis or epydid-
ymo-orchitis) together with speciﬁc antibodies at signiﬁcant
titres or seroconversion. Signiﬁcant titres were considered to
be a standard tube agglutination test (SAT) score of ‡1 ⁄ 160 and
an immunocapture agglutination test score of ‡1 ⁄ 320.
Microbiological studies
Two blood cultures, the rose Bengal test, the SAT and the
immunocapture-agglutination test were performed for all
patients with active brucellosis, febrile syndromes of other
aetiologies or a history of brucellosis, and for subjects perma-
nently exposed to Brucella.
Blood samples were incubated in a non-radiometric semi-
automatic BACTEC 9240 system (Becton Dickinson, Diagnos-
tic Instrument Systems, Sparks, MD, USA). Blood cultures
were processed according to usual techniques. Incubation was
maintained for 15 days, with blind subcultures on chocolate
agar and Brucella agar being performed after 7 and 15 days.
These subcultures were incubated at 37C in a 5–10% CO2
atmosphere for 3 days. All isolates were identiﬁed according
to normalized protocols [14]. Serological tests were all per-
formed as previously described [15,16].
DNA extraction from serum samples
Serum samples for PCR were taken at the same time as the
blood cultures. Two aliquots of serum were conserved at
)20C until processing. DNA was extracted using the Ultra-
Clean DNA-BloodSpin Kit (Mo Bio Laboratories, Carlsbad,
CA, USA). Prior to DNA extraction, 200 lL of serum was
centrifuged for 15 min at 15 000 g. The supernatant was
discarded, and the pellet was resuspended with the volume
of buffer speciﬁed in the manufacturer’s instructions. DNA
pellets were resuspended in 200 lL of molecular biology-grade
water. Finally, DNA was concentrated by adding 8 lL of 5 M
NaCl and 400 lL of 100% cold ethanol, mixed, and centrifuged
at 15 000 g for 5 min. The DNA pellets were brought to a ﬁnal
volume of 40 lL in water, and stored at 4C until use. Aliquots
of 5 lL of the suspension were used for PCR analysis.
Primer and probe design
The Brucella spp.-speciﬁc sequences of the PCR primers and
probe were selected from the conserved region of the gene
encoding an immunogenic membrane protein of 31 kDa
(BCSP31) speciﬁc to the Brucella genus, which is present in all
known biovars (Gen-Bank M-20404). Primers were designed
with Beacon Designer Software (Premier Biosoft International,
Palo Alto, CA, USA) and synthesized by Proligo (Sigma-Aldrich
Co., Paris, France). The sequences of theprimers and theTaqMan
probe were as follows: forward primer, Tq1, 5¢-TGCCGGAG
CCTATAAGGACG-3¢; reverse primer, Tq2, 5¢-CGAGTGCCTT
GCGTGTATCC-3¢; and TaqMan probe, Stq, 5¢-ACCGACCC
TTGCCGTTGCCGC-3¢. The Stq TaqManprobewas ﬂuorescence
labelled at the 5¢-end with 6-carboxyﬂuorescein phosphorami-
dite (FAM) as the reporter dye, and at the 3¢-end with
5-carboxytetramethylrhodamine (TAMRA) as the quencher.
Primer and probe sequences were checked for speciﬁcity using
a BLAST search, and no signiﬁcant matches were found.
Plasmid construction
The ampliﬁcation product of 140 bp from Brucella abortus B-19
obtained with primers Tq1 and Tq2 was puriﬁed from the
agarose gel using the gel extraction kit QIAquick (QIAGEN,
Hilden, Germany), according to the manufacturer’s instruc-
tions. The puriﬁed PCR amplicon was cloned into PCR2.1-
TOPO and transferred into Escherichia coli DH-5 alpha using
the TOPO-TA cloning kit (Invitrogen, Barcelona, Spain). The
plasmid DNAs were puriﬁed using the QIAprep Spin Mini-
prep (QIAGEN), linearized by digestion with EcoRI (Roche,
Barcelona, Spain), and sequenced to conﬁrm the identity of the
inserted bacterial DNA (Laboratorio de Secuenciacio´n de
Sistemas Geno´micos, Valencia, Spain). The absorbance of the
DNA solution was measured three times at 260 nm in a
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NANODROP ND-1000 spectrophotometer (Nano Drop Tech-
nologies, Inc., Wilmington, DE, USA), and dilutions of plasmid
DNAs were used as standards for subsequent PCR analysis.
Standard curve construction
Plasmid standards containing 2 · 104 to 2 · 100 copies per
reaction were prepared by diluting the puriﬁed plasmid in
water.
All standards were ampliﬁed in quadruplicate. The stan-
dard curve was generated and exported using the LightCycler
software v.4.0. It was subsequently loaded as an external
standard curve after each run and calibrated, with a calibra-
tor ⁄positive control being included in all runs.
LC Q-PCR
PCRs were performed in 20-lL ﬁnal volumes in capillary tubes
in a LightCycler instrument (Roche Diagnostic, Mannheim,
Germany). Reaction mixtures contained 4 lL of LightCycler
FastStart DNA MasterPLUS HybProbe (Roche Diagnostic), each
primer at 0.6 lM, Taqman probe at 200 nM, and between 50–
100 ng of template DNA.
All capillaries were sealed, and centrifuged at 500 g for 5 s,
and the DNAs were ampliﬁed in the LightCycler, with activa-
tion of polymerase (95C for 10 min), followed by 45 cycles of
10 s at 95C, 20 s at 60C, and 6 s at 72C. The temperature
transition rate was 20C ⁄ s for all steps. The concentration of
Brucella DNA present in the clinical samples was calculated by
LightCycler software. The crossing point (Cp or threshold cycle)
was deﬁned as the maximum of the second derivative from the
ﬂuorescence curve. All runs included a negative water control
and calibrator ⁄positive control. The positive control contained
2 · 104 copies of the plasmid per reaction. All samples were
processed in duplicate and, to be considered positive, both
replicates had to be positive. The ﬁnal bacterial DNA load was
taken to be the mean value of the two separate samples. To
prevent contamination, universal precautions were taken and
one-way ﬂow of DNA extraction and ampliﬁcation was used.
To avoid potential observer bias, the status of each patient, with
respect to Brucella infection, was unknown during the PCR
assay. PCR analyses were considered to be negative for Brucella
DNA if the Cp values exceeded 45 cycles.
Statistical analysis
The Student t-test and ⁄ or Mann–Whitney test were used to
compare continuous variables, and the v2 test or Fisher test to
compare categorical variables. A p-value of <0.05 was consid-
ered to be statistically signiﬁcant. The diagnostic accuracy was
assessed by calculating the area under receiver operating
characteristic (ROC) curves. Sensitivity, speciﬁcity, positive
and negative predictive values, likelihood ratios (LRs) and




The analytical sensitivity of the LC Q-PCR was
initially determined by amplifying ten-fold seri-
ally diluted plasmid DNA with a detection limit
of 2 · 100 copies per reaction. The assay showed a
linear quantitative range over ﬁve orders of
magnitude from 2 · 105 down to 2 · 100 copies
per reaction, with a linear regression equation of
Cp = )3.32 log (copy no.) + 36.93, correlation
coefﬁcient (R2) value of 0.99, and a PCR efﬁciency
(E) of 2.0.
When DNA templates prepared from serum
spiked with serial dilutions of B. abortus B-19 cells
were used, the analytical sensitivity was found to
be 2 · 100 genomic copies per reaction (equiva-
lent to 1 · 101 fg of DNA). A linear regression of
over ﬁve orders of magnitude was found, from
2 · 105 down to 2 · 100 copies per reaction. The
equation for the linear regression line for the
standard curve generated and its corresponding
E and R2 values were Cp = )3.23 log (copy no.) +
35.63, R2 = 0.99 and E = 2.0.
Reproducibility
Intra-assay variability was determined by ampli-
fying, in quadruplicate, diluted plasmid DNA,
equivalent to 2 · 104 to 2 · 100 copies per reac-
tion. Cp values obtained for the same dilutions on
ﬁve different days were used to determine the
inter-assay variability. The mean coefﬁcients of
variation for intra-assay and inter-assay repeti-
tions were 0.8% and 1.5%, respectively.
Patient characteristics
Of the 46 patients with brucellosis, 28 (60.9%)
were men and 18 (39.1%) women. The mean age
was 42.5 ± 16.4 years (range, 15–81 years). The
mean duration of the symptoms prior to diagno-
sis was 7.3 ± 11.1 weeks (range, 1–65 weeks).
Twenty-eight patients (60.9%) had fever with
no apparent focus, and 18 (39.1%) had focal
complications (eight with vertebral osteomyelitis,
six with orchiepididymitis, two with meningoen-
cephalitis, and one each with sternoclavicular
arthritis and liver abscess).
Blood cultures were positive in 32 patients
(69.6%). All isolated strains were identiﬁed as
Brucella melitensis. The SAT and the immunocap-
ture-agglutination test yielded titres within the
diagnostic range in 67.4% and 89.1% of cases,
respectively. Both tests had negative results or
yielded titres below the diagnostic range in 10.8%
of cases.
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Forty-four (95.7%) patients with brucellosis had
a positive LC Q-PCR result vs. ﬁve (7.8%) of the 64
control patients. The patients with a false-negative
LC Q-PCR result were two male shepherds (24
and 57 years old)with a febrile syndrome and from
whose blood cultures B. melitensis was isolated.
Four of the ﬁve controls with a positive LC Q-PCR
result were patients with brucellosis who had just
completed treatment with doxycycline plus strep-
tomycin, and the ﬁfth was a veterinary surgeon
involved in the caprine vaccination and sacriﬁce
campaigns, who, for 10 days, had fever and
arthralgia that were self-limiting with symptom-
atic treatment. The blood cultures from this patient
were always negative, and he remained asymp-
tomatic over the following 12 months; the two LC
Q-PCR controls during this period were negative.
Thus, qualitatively, the sensitivity, speciﬁcity,
positive predictive value and negative predictive
value of the LC Q-PCR assay were 95.7%, 92.2%,
89.8% and 96.7%, respectively, with a positive LR
of 12.2 (95% CI 5.3–28.5) and negative LR of 0.05
(95% CI 0.01–0.18).
Quantiﬁcation of bacterial DNA load in clinical
samples
The mean threshold cycles for the brucellosis
patients and controls were 31.8 ± 1.7 and
35.5 ± 1.1, respectively (p <0.001). The mean bac-
terial DNA load for patients with brucellosis was
8.2 · 106 copies ⁄mL (range, 4.1 · 103 to
3.2 · 108 copies ⁄mL) vs. 3.3 · 103 copies ⁄mL
(range, 6.0 · 100 to 2.1 · 105 copies ⁄mL) for the
controls.
Among the 46 brucellosis patients, 43 (93.5%)
had a bacterial DNA load of >105 copies ⁄mL,
whereas none of the four controls with a positive
LC Q-PCR result after treatment had a bacterial
DNA load of >4 · 103 copies ⁄mL.
The best cut-off for LC Q-PCR bacterial DNA
load in serum samples was 5 · 103 copies ⁄mL. At
this cut-off, 43 of the 46 patients with active
brucellosis were correctly classiﬁed, with sensi-
tivity of 93.5% (95% CI 86.3–100%) and speci-
ﬁcity of 98.4% (95% CI 95.4–100%). The positive
and negative LRs were 59.8 (95% CI 8.5–418.9)
and 0.07 (95% CI 0.02–0.20), respectively. Deter-
mination of the maximum speciﬁcity required
raising the cut-off to 2.2 · 105 copies ⁄mL, at
which level the sensitivity fell to 76.1%
(95% CI 63.8–88.4%). Fig. 1 shows the ROC
curves for LC Q-PCR bacterial DNA load in
serum samples. Table 1 shows the diagnostic
yield of the LC Q-PCR in different situations.
DISCUSSION
One of the most difﬁcult problems in diagnosing
human brucellosis concerns the presence of indi-
viduals who are serologically positive and are
either asymptomatic or oligosymptomatic.
Human brucellosis shows a marked tendency to
relapse after conclusion of treatment [17–19].
Even with the correct treatment, the incidence of
relapse in cases of brucellosis remains high,
Fig. 1. Area under the receiver operating characteristic curves (ROC AUC) for testing the ability of the LC Q-PCR to
distinguish active from inactive brucellosis. ROC curves were constructed by plotting sensitivity and 1-speciﬁcity
corresponding to each cut-off value for the Brucella DNA load. (a) Considering a cut-off of 5 · 103 copies ⁄mL. (b)
Considering a cut-off of 2.2 · 105 copies ⁄mL to achieve a speciﬁcity of 100%.
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ranging from 5% to 23% in the largest series
reported [20–24].
As with other infections caused by fastidious
microorganisms, molecular techniques have pro-
ven to be more efﬁcient than conventional meth-
ods in speciﬁc clinical cases of Brucella infection.
However, the relative complexity of these
techniques, the lack of standardized procedures
and, occasionally, socio-economic limitations in
the most affected countries have hindered the
development and implementation of these tech-
niques [25].
Very few studies have examined the possible
usefulness of PCR-based methods for discrimi-
nating between active and past brucellosis, and
some of these have important biases that make
interpretation of the results difﬁcult [13].
In a previous study using a single-step conven-
tional PCR in whole blood samples, our group
reported that 96.4% of the patients had a negative
PCR result upon conclusion of treatment [26].
Similar results have been communicated by oth-
ers [8].
In the present study, the sensitivity and spec-
iﬁcity of the LC Q-PCR were 95.7% and 92.2%,
respectively. Thus, qualitatively considered, the
diagnostic yield of the LC Q-PCR is clearly better
than that of conventional microbiological meth-
ods. Similar ﬁndings have recently been reported
by Navarro et al. [12], who ampliﬁed a speciﬁc
sequence of B. melitensis. Unfortunately, the con-
trol group in that study included only healthy
blood donors. Therefore,no conclusions could be
drawn concerning the utility of the LC Q-PCR in
other scenarios where it is necessary to eliminate
the presence of active brucellosis [12].
Previous studies have reported that 2–5% of
patients with recent brucellosis, or asymptomatic
subjects permanently exposed to the disease, may
have a positive PCR result with persistently
negative blood cultures [27]. Hypothetically, in
these subjects, bacteraemia, if it exists, should be
very low and closely associated with the amount
of circulating DNA.
The LC Q-PCR technology described here
allows quick, sensitive and reproducible mea-
surement of the bacterial DNA load. This load
was signiﬁcantly higher in the patients with active
brucellosis than in the controls for whom PCR
results were positive. These results are especially
important in relation to the rigorous criteria for
the control group.
Determining the ROC curves is a validated way
ofmeasuring the diagnostic accuracy of a test or the
discriminative power of a prediction rule [28]. The
cut-off value that maximized the sum of sensitivity
and speciﬁcity for discrimination between active
and past brucellosis was 5 · 103 copies ⁄mL. With
this value, the area under the ROC curve for active
brucellosis was 0.963. Thus, considering the entire
sample, this cut-offwould ensure 93.5% sensitivity
and a 97.7% positive predictive value in cases of
active brucellosis.
Evidence exists that some highly exposed
persons, i.e. veterinary surgeons who undertake
vaccination campaigns, abattoir workers, and
herdsmen who assist their animals in giving
birth, may have self-limiting infections after
inoculation [29]. This may be the explanation for
the high bacterial DNA load in one of our control
samples. The repeatedly negative PCR results
over the following months support this possibil-
ity. If we consider that this is what happened in
the only person in the control group who had an
LC Q-PCR result with a bacterial DNA load
higher than 103 copies ⁄mL, and thus exclude this
person from the overall analysis, the sensitivity
and positive predictive value of this cut-off would
be 93.5% and 100%, respectively.
Using similar technology, Navarro et al. consis-
tently detected B. melitensis DNA in blood sam-
ples of patients with brucellosis throughout
treatment and follow-up, despite apparent recov-
ery from infection [12]. The heterogeneity of the
Table 1. Diagnostic yield: comparison between blood cultures and LC Q-PCR in serum samples
Sensitivity Speciﬁcity PPV (%) NPV (95% CI) Positive LR Negative LR
Blood cultures 69.6 (56.3–82.9) 100 100 78.8 (68.9–88.7) NDa 0.30 (0.20–0.47)
LC Q-PCR, all samples (cut-off ‡ 5x103 copies ⁄mL) 93.5 (86.3–100) 98.4 (95.4–100) 97.7 (93.3–100) 95.5 (90.4–100) 59.9 (84–418.9) 0.07 (0.02–0.2)
LC Q-PCR, excluding outlierb (cut-off ‡ 5·103 copies ⁄mL) 93.5 (86.3–100) 100 100 95.5 (90.4–100) NDa 0.07 (0.02–0.19)
LC Q-PCR, all samples (cut-off ‡ 2·105 copies ⁄mL) 73.9 (62.1–86.6) 100 100 84.2 (76.0–92.4) NDa 0.26 (0.16–0.42)
PPV, positive predictive value; NPV, negative predictive value; positive LR, positive likelihood ratio;
negative LR, negative likelihood ratio.
a Not done for mathematical reasons (division by zero).
b Veterinary surgeon with self-limiting symptoms.
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treatment used in that study and the high rate of
relapse reported (seven of 18 patients, 38.8%) are
completely ouside the norm of usual clinical
practice; this may explain, in part, the discrepancy.
Another possible explanation is the manner of
interpreting the results, as Navarro et al. consid-
ered a result to be positive if just one of three
replicates was positive [12]. The fact that the DNA
load in the present study was higher than that
reported by Navarro et al. is clearly related to the
type of sample used and to the efﬁciency of the
method. Navarro et al. used whole blood samples,
and their PCRmixture contained 400 ng of human
DNA, both of which can have a negative effect on
the efﬁciency of the ampliﬁcation process.
Serum could be a better sample, as it reduces
inhibition by haemoglobin, human DNA, or any
other substance present in whole blood, and does
not require red blood cell lysis, washings by
centrifugation, or measurement and adjustment
of isolated DNA [30].
In conclusion, the LC Q-PCR using serum
samples appears to be a useful method, not only
for the initial diagnosis of brucellosis, but also
for the differentiation between active and past
brucellosis.
ACKNOWLEDGEMENTS
We thank I. Johnstone for his help with the English language
version of the text.
TRANSPARENCY DECLARATION
This work received ﬁnancial support from Instituto de Salud
Carlos III (ISCIII), Red Tema´tica para la Investigacio´n en
Brucelosis (grant G03 ⁄ 204), F.I.S (grant PI06 ⁄ 0495), and Con-
sejerı´a de Innovacio´n Ciencia y Empresa (grant CTS-276) and
Consejerı´a de Salud (grant 152 ⁄ 04), both of Junta de Andalucı´a
(Spain).
None of the authors has any conﬂict of interest with respect
to products mentioned in this study.
REFERENCES
1. Corbel MJ. Brucellosis an overview. Emerg Infect Dis 1997;
3: 213–221.
2. Lin J, Ficht TA. Protein synthesis in Brucella abortus
induced during macrophage infection. Infect Immun 1995;
63: 1409–1414.
3. Ariza J. Brucelosis en el siglo XXI. Med Clin (Barc) 2002;
119: 339–344.
4. Colmenero JD, Reguera JMª, Martos F et al. Complications
associated with Brucella melitensis infection: a study of 530
cases. Medicine (Baltimore) 1996; 75: 195–211.
5. Young EJ. An overview of human brucellosis. Clin Infect
Dis 1995; 21: 283–289.
6. Ariza J, Pellicer T, Pallares R et al. Speciﬁc antibody proﬁle
in human brucellosis. Clin Infect Dis 1992; 14: 131–140.
7. Young EJ. Serologic diagnosis of human brucellosis:
analysis of 214 cases by agglutination tests and review of
the literature. Rev Infect Dis 1991; 13: 359–367.
8. Kattar MM, Zalloua PA, Araj GF et al. Development and
evaluation of real-time polymerase chain reaction assays
on whole blood and parafﬁn-embedded tissues for rapid
diagnosis of human brucellosis. Diagn Microbiol Infect Dis
2007; 59: 23–32.
9. Debeaumont C, Falconnet PA, Maurin M. Real-time PCR
for detection of Brucella spp. DNA in human serum sam-
ples. Eur J Clin Microbiol Infect Dis 2005; 24: 842–845.
10. Vrioni G, Gartzonika C, Kostoula A et al. Application of a
polymerase chain reaction enzyme immunoassay in
peripheral whole blood and serum specimens for diag-
nosis of acute human brucellosis. Eur J Clin Microbiol Infect
Dis 2004; 23: 194–199.
11. Morata P, Queipo-Ortun˜o MI, Reguera JMª et al. Diag-
nostic yield of a PCR-assay in focal complications of
brucellosis. J Clin Microbiol 2001; 39: 3743–3746.
12. Navarro E, Segura JC, Castan˜o MJ et al. Use of real-time
quantitative polymerase chain reaction to monitor the
evolution of Brucella melitensis DNA load during therapy
and post-therapy follow-up in patients with brucellosis.
Clin Infect Dis 2006; 42: 1266–1273.
13. Maas KS, Me´ndez M, Zavaleta M et al. Evaluation of
brucellosis by PCR and persistence after treatment in
patients returning to the hospital for follow-up. Am J Trop
Med Hyg 2007; 76: 698–702.
14. Moyer N, Holcomb PLA. Brucella. In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds, Manual of clinical
microbiology, 6th edn. Washington, DC: American Society
for Microbiology, 1995; 382–386.
15. Alton GG, Jones LM, Pietz DE. Laboratory techniques in
brucellosis, 2nd edn. Geneva, Switzerland: World Health
Organization, 1975.
16. Ordun˜a A, Almaraz A, Prado A et al. Evaluation of an
immunocapture-agglutination test (Brucellacapt) for the
serodiagnosis of human brucellosis. J Clin Microbiol 2000;
38: 4000–4005.
17. Pappas G, Akritidis N, Bosilkovski M et al. Brucellosis.
N Engl J Med 2005; 352: 2325–2336.
18. Ariza J, Correidora J, Pallare´s R et al. Characteristics of and
risk factors for relapse of brucellosis in humans. Clin Infect
Dis 1995; 20: 1241–1249.
19. Solera J, Martinez-Alfaro E, Espinosa A et al. Multivariate
model for predicting relapses in human brucellosis. J Infect
1998; 36: 85–92.
20. Ariza J, Gudiol F, Pallares R et al. Treatment of human
brucellosis with doxycycline plus rifampin or doxycyclin
plus streptomycin. Ann Intern Med 1992; 117: 25–30.
21. Montejo JM, Albert I, Zarate PG et al. Open randomized
therapeutic trial of six antimicrobial regimens in the treat-
ment of human brucellosis. Clin Infect Dis 1993; 16: 671–676.
22. Solera J, Geijo P, Largo J et al. A randomized, double blind
study to assess the optimal duration of doxycycline
treatment for human brucellosis. Clin Infect Dis 2004; 39:
1776–1782.
23. Colmenero-Castillo JD, Hernandez-Marquez S, Reguera-
Iglesias JM et al. Comparative trial of doxycycline plus
Queipo-Ortun˜o et al. Diagnosis of brucellosis by quantitative PCR 1133
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 1128–1134
streptomycin versus doxycycline plus rifampin for
therapy of human brucellosis. Chemotherapy 1989; 35:
146–152.
24. Hasanjani-Roushan MR, Mohraz M, Hajiahmadi M et al.
Efﬁcacy of gentamicin plus doxycycline versus strepto-
mycin plus doxycycline in the treatment of brucellosis in
humans. Clin Infect Dis 2006; 42: 1075–1080.
25. Navarro E, Casao MA, Solera J. Diagnosis of human bru-
cellosis using PCR. Expert Rev Mol Diagn 2004; 4: 115–123.
26. Morata P, Queipo-Ortun˜o MI, Reguera JM et al. Post-
treatment followup of brucellosis by PCR assay. J Clin
Microbiol 1999; 37: 4163–4166.
27. Al-Nakkas A, Mustafa AS, Wright SG. Large-scale evalu-
ation of a single-tube nested PCR for the laboratory diag-
nosis of human brucellosis in Kuwait. J Med Microbiol 2005;
54: 727–730.
28. Hanley JA, McNeil B. The meaning and use of the area
under a receiver operating characteristic (ROC) curve.
Radiology 1982; 143: 29–36.
29. Henderson RJ, Hill DM, Vickers AA et al. Brucellosis and
veterinary surgeons. BMJ 1975; 2: 656–659.
30. Zerva L, Bourantas K, Mitka S et al. Serum is the preferred
clinical specimen for diagnosis of human brucellosis by
PCR. J Clin Microbiol 2001; 39: 1661–1664.
1134 Clinical Microbiology and Infection, Volume 14 Number 12, December 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 1128–1134
